title: Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: p38, nuclear factor κB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway.
abstract: OBJECTIVE
  The retinal pigment epithelium (RPE) is a major source of vascular endothelial growth factor (VEGF) in the eye. Despite the role of VEGF in ocular pathology, VEGF is an important factor in maintaining the choroid and the RPE. Accordingly, the VEGF is constitutively expressed in RPE. In this study, the regulation of constitutive VEGF expression was investigated in an RPE/choroid organ culture.
  
  
  METHODS
  To investigate VEGF regulation, RPE/choroid of porcine origin were used. VEGF content was evaluated with enzyme-linked immunosorbent assay. The influence of several molecular factors was assessed with commercially available inhibitors (SU1498, bisindolylmaleimide, LY294002, nuclear factor kappaB [NFkB] activation inhibitor, mithramycin, YC-1, Stattic, SB203580). For toxicity measurements of inhibitors, primary RPE cells of porcine origin were used, and toxicity was evaluated with methyl thiazolyl tetrazolium assay.
  
  
  RESULTS
  VEGF secretion as measured in the RPE/choroid organ culture was diminished after long-term (48 h) inhibition of vascular endothelial growth factor receptor-2 by VEGFR-2-antagonist SU1498. VEGF secretion was also diminished after phosphatidylinositol 3 kinase was inhibited by LY294002 for 48 h. Coapplication of the substances did not show an additive effect, suggesting that they use the same pathway in an autocrine-positive VEGF regulation loop. Inhibition of protein kinase C by bisindolylmaleimide, on the other hand, did not influence VEGF secretion in organ culture. Inhibition of the transcription factor SP-1 by mithramycin displayed effects after 24 h and 48 h. Inhibiting hypoxia-inducible factor-1 (HIF-1) and Stat3 did not show any influence on constitutive VEGF secretion. Inhibition of the transcription factor NFkB diminished VEGF secretion after 6 h (earliest measured time point) and remained diminished at all measured time points (24 h, 48 h). The same pattern was found when the inhibitor of mitogen-activated kinase p38 was applied. A combination of NFkB and p38 inhibitors displayed an additive effect, completely abolishing VEGF secretion.
  
  
  CONCLUSIONS
  Constitutive VEGF secretion in the RPE/choroid seems to be regulated by the transcription factor NFkB and the mitogen-activated kinase p38 in an independent manner. Constitutive VEGF secretion may be regulated to a lesser extent by the transcription factor SP-1, while Stat3 and hypoxia-inducible factor-1 do not seem to be involved. Additionally, VEGF secretion seems to be regulated long-term by an autocrine positive loop via vascular endothelial growth factor receptor-2 and phosphatidylinositol 3 kinase.
authors: University of Kiel, University Medical Center, Department of Ophthalmology, Kiel, Germany. aklettner@auge.uni-kiel.de
authors: Alexa
authors: A
authors: Klettner
authors: Daniel
authors: D
authors: Westhues
authors: Jens
authors: J
authors: Lassen
authors: Sofia
authors: S
authors: Bartsch
authors: Johann
authors: J
authors: Roider
mesh_terms: D000818:Animals; D002829:Choroid / Q000187:drug effects / Q000378:metabolism*; D002867:Chromones / Q000494:pharmacology; D002934:Cinnamates / Q000494:pharmacology; D003499:Cyclic S-Oxides / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007191:Indazoles / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000502:physiology; D008301:Maleimides / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D009924:Organ Culture Techniques; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D008926:Plicamycin / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D034421:Sus scrofa; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D002867:Chromones; D002934:Cinnamates; D003499:Cyclic S-Oxides; D007093:Imidazoles; D007191:Indazoles; D007211:Indoles; D008301:Maleimides; D009025:Morpholines; D016328:NF-kappa B; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D008926:Plicamycin; D011725:Pyridines; D014157:Transcription Factors; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2; D048051:p38 Mitogen-Activated Protein Kinases; C483044:SU 1498; C517409:stattic; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C088060:bisindolylmaleimide; C093642:SB 203580
references: J Biol Chem. 2000 Aug 25;275(34):26484-91
references: 10849421
references: J Biol Chem. 2011 Jul 8;286(27):23717-24
references: 21566137
references: J Cell Sci. 2003 Feb 15;116(Pt 4):665-74
references: 12538767
references: J Neurosci. 1995 Jul;15(7 Pt 1):4738-47
references: 7623107
references: J Neurosci. 2006 Nov 29;26(48):12439-46
references: 17135405
references: Angiogenesis. 2010 Dec;13(4):327-35
references: 20872175
references: J Neurosci. 2011 May 4;31(18):6858-70
references: 21543616
references: Ophthalmologica. 2010;224 Suppl 1:8-15
references: 20714176
references: Mol Pharmacol. 2010 Mar;77(3):348-67
references: 20008515
references: Cell Res. 2011 Feb;21(2):223-44
references: 21243012
references: Invest Ophthalmol Vis Sci. 2011 Dec 09;52(13):9478-87
references: 22058334
references: Mol Vis. 2004 May 17;10:341-50
references: 15162095
references: Int J Tissue React. 2002;24(4):137-42
references: 12779248
references: Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):996-1002
references: 12483322
references: Exp Eye Res. 2007 May;84(5):812-22
references: 17331500
references: Curr Eye Res. 2006 Sep;31(9):775-85
references: 16966150
references: Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2115-21
references: 10440268
references: Int J Mol Sci. 2012;13(8):9478-88
references: 22949809
references: Retina. 2012 Sep;32(8):1652-63
references: 22466477
references: Prog Retin Eye Res. 2010 Mar;29(2):144-68
references: 20044062
references: Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2814-23
references: 17525217
references: Eur J Pharmacol. 2011 Sep;666(1-3):12-8
references: 21620822
references: Cancer Res. 1996 Aug 1;56(15):3540-5
references: 8758924
references: Ophthalmologica. 2007;221(6):411-7
references: 17947829
references: J Biol Chem. 1994 Feb 18;269(7):5241-8
references: 8106507
references: Ophthalmic Res. 2010;43(3):122-33
references: 19887877
references: PLoS One. 2008;3(11):e3554
references: 18978936
references: J Pharmacol Toxicol Methods. 2010 Nov-Dec;62(3):227-35
references: 20685311
references: Curr Eye Res. 2008 Nov;33(11):984-93
references: 19085381
references: Nature. 1996 Apr 4;380(6573):439-42
references: 8602242
references: Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5222-9
references: 18689706
references: Oncogene. 2002 Mar 27;21(13):2000-8
references: 11960372
references: Exp Nephrol. 1999 Sep-Dec;7(5-6):394-406
references: 10559637
references: Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1190-7
references: 19834034
references: Acta Ophthalmol. 2012 Jun;90(4):299-309
references: 22112056
references: J Cell Physiol. 2012 Jan;227(1):116-26
references: 21374591
references: Med Sci Monit. 2004 Apr;10(4):RA89-98
references: 15039660
references: Trends Mol Med. 2009 May;15(5):217-24
references: 19380253
references: Cutan Ocul Toxicol. 2010 Jun;29(2):122-9
references: 20380623
references: Curr Eye Res. 1995 Nov;14(11):1015-20
references: 8585929
references: Biochem Biophys Res Commun. 1992 Jun 15;185(2):553-8
references: 1535193
references: Adv Exp Med Biol. 2010;664:15-9
references: 20237997
references: J Biol Chem. 1991 Aug 25;266(24):15771-81
references: 1874734
references: Dev Biol. 2003 Dec 1;264(1):275-88
references: 14623248
references: Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):777-83
references: 15103470
references: Biochem Pharmacol. 2001 Apr 15;61(8):947-54
references: 11286986
references: Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4523-7
references: 18441313
references: Biochem J. 2000 Oct 1;351(Pt 1):95-105
references: 10998351
references: Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4942-55
references: 20554621
references: J Mol Med (Berl). 2009 Feb;87(2):117-23
references: 19009282
references: Am J Pathol. 2007 Jul;171(1):53-67
references: 17591953
references: J Pathol. 1998 Nov;186(3):306-12
references: 10211121
references: Med Res Rev. 2008 Mar;28(2):185-200
references: 17457812
references: Chem Biol. 2006 Nov;13(11):1235-42
references: 17114005
references: Nature. 1996 Apr 4;380(6573):435-9
references: 8602241
references: Graefes Arch Clin Exp Ophthalmol. 2009 Nov;247(11):1487-92
references: 19603178
references: Biochemistry. 1998 Nov 24;37(47):16573-81
references: 9843424
references: J Clin Immunol. 2009 Jul;29(4):397-405
references: 19408108
references: Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18751-6
references: 19841260
references: Cardiovasc Res. 2005 Feb 15;65(3):564-73
references: 15664382
references: J Biol Chem. 1998 Nov 13;273(46):30336-43
references: 9804796
references: Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3135-42
references: 16799060
references: Bioorg Med Chem. 2003 Feb 6;11(3):383-91
references: 12517433
references: Mol Vis. 2012;18:114-20
references: 22275802
references: Basic Res Cardiol. 2011 Mar;106(2):217-31
references: 21174212
references: Cell Cycle. 2008 Aug 15;7(16):2553-61
references: 18719373
references: J Exp Med. 2005 May 16;201(10):1615-25
references: 15883173
references: J Biol Chem. 2008 Apr 25;283(17):11435-44
references: 18305118
references: Biochem Pharmacol. 2004 Nov 15;68(10):1923-8
references: 15476663
references: Graefes Arch Clin Exp Ophthalmol. 1997 Mar;235(3):159-67
references: 9085111